Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology
Cambridge, MA, and Paris, France– October 13, 2021 Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading…
Keep up to date with all of our latest news.
SparingVision Conference Participation in H2 2021
SparingVision announces the scientific and investor conferences that its management team will be participating in…
SparingVision to Present at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting
SparingVision is pleased to announce that it will present a poster highlighting the Company’s recent…
SparingVision Presents Three Posters at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
SparingVision is pleased to announce that it has presented three posters highlighting the Company’s recent…
SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics
Adds unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis…
SparingVision Announces Upcoming Poster Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2021 Virtual Annual Meeting
An abstract on rod-derived cone viability factor (RdCVF) in pig models of Retinitis Pigmentosa (RP)…
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
Three abstracts highlighting the company’s recent research into ocular diseases and its lead gene therapy…
SparingVision Conference Participation in H1 2021
SparingVision announces the conferences that its management team will be participating in in the first…
Dr. Daniel C. Chung appointed as Chief Medical Officer of SparingVision
Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of…
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board Paris, January…
SparingVision Strengthens Management Team
• Dr. Florence Lorget to lead development sciences as Chief Development Sciences Officer • Dr.…
News & Media Menu
LATEST TWEETS
We are pleased to share our new video with our CEO @Boissel Stephane & @intelliatweets CSO @LauraSepplore, announcing our collaboration with @Intellia to develop novel #genomicmedicines using #CRISPRCas9 technology to treat #ocular diseases. https://sparingvision.com/intellia-therapeutics-and-sparingvision-announce-strategic-collaboration-to-develop-novel-ocular-therapies-%e2%80%a8using-crispr-cas9-technology/
PARTNERS
